Foreign governments have underpaid for innovative medicines for too long. The answer is not to import their price controls into the United States but to make wealthy countries shoulder more of the cost of innovation.
President Trump just announced another round of agreements with pharmaceutical companies under his “most-favored-nation” drug pricing initiative.
The nine new deals bring the total number of participating manufacturers to 26, covering nearly 90% of the branded-drug market.
The campaign targets a real problem. Many wealthy countries use price controls to pay far less for new medicines than Americans do.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Use Trade Policy to Push Wealthy Nations to Pay More for Meds
Sally C. Pipes
Foreign governments have underpaid for innovative medicines for too long. The answer is not to import their price controls into the United States but to make wealthy countries shoulder more of the cost of innovation.
President Trump just announced another round of agreements with pharmaceutical companies under his “most-favored-nation” drug pricing initiative.
The nine new deals bring the total number of participating manufacturers to 26, covering nearly 90% of the branded-drug market.
The campaign targets a real problem. Many wealthy countries use price controls to pay far less for new medicines than Americans do.
Read more here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.